Cargando…

Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis

[Image: see text] Multiple effects on cancer cells are exerted by the peroxisome proliferator-activated receptor γ (PPAR-γ). Recent studies have shown that rosiglitazone, a synthetic PPAR-γ ligand, inhibits the growth of cells. This research was designed to assess the impact of rosiglitazone on diet...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanqiao, Sreeharsha, Nagaraja, Sharma, Sanjay, Mishra, Anurag, Singh, Avinash Kumar, Gubbiyappa, Shiva Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081392/
https://www.ncbi.nlm.nih.gov/pubmed/32201822
http://dx.doi.org/10.1021/acsomega.9b04357
_version_ 1783508165323653120
author Wu, Yanqiao
Sreeharsha, Nagaraja
Sharma, Sanjay
Mishra, Anurag
Singh, Avinash Kumar
Gubbiyappa, Shiva Kumar
author_facet Wu, Yanqiao
Sreeharsha, Nagaraja
Sharma, Sanjay
Mishra, Anurag
Singh, Avinash Kumar
Gubbiyappa, Shiva Kumar
author_sort Wu, Yanqiao
collection PubMed
description [Image: see text] Multiple effects on cancer cells are exerted by the peroxisome proliferator-activated receptor γ (PPAR-γ). Recent studies have shown that rosiglitazone, a synthetic PPAR-γ ligand, inhibits the growth of cells. This research was designed to assess the impact of rosiglitazone on diethylnitrosamine (DENA)-induced lung carcinogenesis in Wistar rats and to study the underlying molecular mechanism. A total of 40 adult male Wistar rats were separated into four groups as follows: group 1 is known as a control. Group 2 is known as the DENA group (150 mg/kg, i.p.). Group 3 and group 4 denote DENA-induced rats treated with 5 and 10 mg/kg rosiglitazone, respectively. Lipid peroxidation, various antioxidant enzymes, histological perceptions, and caspase-3, Bcl2, and Bax gene expression were measured in lung tissues. Rosiglitazone treatment reverted the DENA-induced changes in the expression of these genes, inflammatory cytokines, and oxidative stress. However, blotting analysis discovered reduced caspase-3 and BAX expressions and elevated Bcl-2 expression in DENA-induced rats. The expression of such proteins causing DENA lung cancer was restored by rosiglitazone therapy.
format Online
Article
Text
id pubmed-7081392
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-70813922020-03-20 Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis Wu, Yanqiao Sreeharsha, Nagaraja Sharma, Sanjay Mishra, Anurag Singh, Avinash Kumar Gubbiyappa, Shiva Kumar ACS Omega [Image: see text] Multiple effects on cancer cells are exerted by the peroxisome proliferator-activated receptor γ (PPAR-γ). Recent studies have shown that rosiglitazone, a synthetic PPAR-γ ligand, inhibits the growth of cells. This research was designed to assess the impact of rosiglitazone on diethylnitrosamine (DENA)-induced lung carcinogenesis in Wistar rats and to study the underlying molecular mechanism. A total of 40 adult male Wistar rats were separated into four groups as follows: group 1 is known as a control. Group 2 is known as the DENA group (150 mg/kg, i.p.). Group 3 and group 4 denote DENA-induced rats treated with 5 and 10 mg/kg rosiglitazone, respectively. Lipid peroxidation, various antioxidant enzymes, histological perceptions, and caspase-3, Bcl2, and Bax gene expression were measured in lung tissues. Rosiglitazone treatment reverted the DENA-induced changes in the expression of these genes, inflammatory cytokines, and oxidative stress. However, blotting analysis discovered reduced caspase-3 and BAX expressions and elevated Bcl-2 expression in DENA-induced rats. The expression of such proteins causing DENA lung cancer was restored by rosiglitazone therapy. American Chemical Society 2020-03-04 /pmc/articles/PMC7081392/ /pubmed/32201822 http://dx.doi.org/10.1021/acsomega.9b04357 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Wu, Yanqiao
Sreeharsha, Nagaraja
Sharma, Sanjay
Mishra, Anurag
Singh, Avinash Kumar
Gubbiyappa, Shiva Kumar
Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title_full Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title_fullStr Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title_full_unstemmed Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title_short Anticancer Effect of Rosiglitazone, a PPAR-γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis
title_sort anticancer effect of rosiglitazone, a ppar-γ agonist against diethylnitrosamine-induced lung carcinogenesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081392/
https://www.ncbi.nlm.nih.gov/pubmed/32201822
http://dx.doi.org/10.1021/acsomega.9b04357
work_keys_str_mv AT wuyanqiao anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis
AT sreeharshanagaraja anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis
AT sharmasanjay anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis
AT mishraanurag anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis
AT singhavinashkumar anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis
AT gubbiyappashivakumar anticancereffectofrosiglitazoneappargagonistagainstdiethylnitrosamineinducedlungcarcinogenesis